BTOG 2018 | Does the UK need a National Optimal Lung Cancer Pathway?

Neal Navani

Long waits for and between treatments, leading to worse outcomes for patients, are unacceptable. Improved care pathways are required to streamline the treatment journey. In this interview, Neal Navani, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the new National Optimal Lung Cancer Pathway (NOLCP). This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Share this video  
Similar topics
Related videos
1:21
BTOG 2020: what to expect
Sanjay Popat
1:48
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe
4:06
Cancer treatment: major milestones & what's next in the 2020s
John Wagstaff
4:48
Minimizing the risk of steroid-induced hyperglycemia in NSCLC patients receiving immunotherapy
Islam Elkonaissi
0:54
SB8: a bevacizumab biosimilar for NSCLC
Martin Reck
Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
BTOG 2018
Interview
24th January 2018
More from Neal Navani
Lung cancer screening in the UK in 2019: where are we now?
Screening for lung cancer in the UK: progress and considerations
EBUS and CT-guided biopsy in repeat biopsies of patients with progressive lung cancer
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals